Advertisement

Topics

Intarcia Therapeutics, Inc. Company Profile

14:24 EST 20th November 2017 | BioPortfolio

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing clinical stage development programs for type 2 diabetes and hepatitis C.


News Articles [540 Associated News Articles listed on BioPortfolio]

US FDA rejects Intarcia's diabetes treatment implant

The US FDA has rejected an implantable diabetes treatment developed by Intarcia Therapeutics, Inc. and asked for more information about how the drug-device combination therapy is made.

Intarcia et Numab franchissent un jalon clé avec le choix d’un candidat-médicament multispécifique pour le traitement des maladies auto-immunes

Friday, September 15th 2017 at 12:06pm UTC Numab va lancer un tour de financement de 30 millions de CHF dans le but de faire progresser les programmes pipelines propriétaires jusqu’au stade cli...

Intarcia Provides Corporate Update

BOSTON, Sept. 27, 2017 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company committed to developing innovative therapies to enhance treatment and preventio...

Intarcia and Numab Reach Key Milestone with Selection of Multi-specific Development Candidate for Autoimmune Disease

Numab to Initiate Financing Round of CHF 30 Million to Bring Proprietary Pipeline Programs to Clinical Stage Intarcia Therapeutics, Inc., and Numab Therapeutics ...

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to deve...

Intarcia gets CRL for Type II diabetes candidate ITCA 650

Manufacturing Issues Force the FDA to Reject Intarcia's Diabetic Drug Pump

  Life Sciences Jobs   ...

New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes

BOSTON, Sept. 15, 2017 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced top-line results from FREEDOM-3S which assessed the tolerability and optimal dosing regimen of two different ITCA 650 ...

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1169 Associated Companies listed on BioPortfolio]

Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of d...

Intarcia Therapeutics, Inc

Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Intarcia Therapeutics, Inc." on BioPortfolio

We have published hundreds of Intarcia Therapeutics, Inc. news stories on BioPortfolio along with dozens of Intarcia Therapeutics, Inc. Clinical Trials and PubMed Articles about Intarcia Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intarcia Therapeutics, Inc. Companies in our database. You can also find out about relevant Intarcia Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record